apricitabine (AVX754) / Takeda, TBG Diagnostics, Zydus Lifesci - LARVOL DELTA

Synthesis of Natural and Sugar-Modified Nucleosides Using the Iodine/Triethylsilane System as N-Glycosidation Promoter. (PubMed, Int J Mol Sci) - "An analysis of reaction stereoselectivity in the absence of C2-positioned stereodirecting groups revealed high selectivity with six-membered substrates, depending on the nucleophilic character of the nucleobase or based on anomerization reactions. The synthetic utility of the Et3SiH/I2-mediated N-glycosidation reaction was highlighted by its use in the synthesis of the investigational drug apricitabine."

Journal

Current insights and molecular docking studies of HIV-1 reverse transcriptase inhibitors. (PubMed, Chem Biol Drug Des) - "Zidovudine, didanosine, and stavudine are FDA-approved NRTIs, while nevirapine, efavirenz, and delavirdine are FDA-approved NNRTIs. Several agents are in clinical trials, including apricitabine, racivir, elvucitabine, doravirine, dapivirine, and elsulfavirine. This review addresses HIV-1 structure, replication cycle, reverse transcription, and HIV drug targets. This study focuses on NRTIs and NNRTIs, their binding sites, mechanisms of action, FDA-approved drugs and drugs in clinical trials, their resistance and adverse effects, their molecular docking studies, and highly active antiretroviral therapy (HAART)."

Journal • Review • Human Immunodeficiency Virus • Infectious Disease

Nucleoside Analog Reverse-Transcriptase Inhibitors in Membrane Environment: Molecular Dynamics Simulations. (PubMed, Molecules) - "The behavior of four drugs from the family of nucleoside analog reverse-transcriptase inhibitors (zalcitabine, stavudine, didanosine, and apricitabine) in a membrane environment was traced using molecular dynamics simulations. It was shown that apricitabine penetrated the hydrophilic part of the POPC and POPG membranes more effectively than the other drugs. Van der Waals interactions between S atoms and lipids were responsible for this."

Journal

Pharmacokinetics Study of GSK1265744 in Subjects With Severe Renal Impairment (clinicaltrials.gov) - P1; N=16; Not yet recruiting; Sponsor: ViiV Healthcare

New P1 trial • Biosimilar • Immunology • Inflammation • Renal Disease

Most Closely Matched 3rd Party Rapidly Generated LMP, BARF1 And EBNA1 Specific CTL, EBV-Positive Lymphoma (MABEL) (clinicaltrials.gov) - P1; N=42; Recruiting; Sponsor: Baylor College of Medicine; Not yet recruiting -> Recruiting

Enrollment open • Biosimilar • Hematological Malignancies • Immunology • Non-Hodgkin’s Lymphoma • Oncology

A Comparison Study Between the Fixed Dose Triple Combination of Fluticasone Furoate/ Umeclidinium/ Vilanterol Trifenatate (FF/UMEC/VI) With Budesonide/Formoterol in Subjects With Chronic Obstructive Pulmonary Disease (COPD) (clinicaltrials.gov) - P3; N=1800; Recruiting; Sponsor: GlaxoSmithKline; Not yet recruiting -> Recruiting

Enrollment open • Biosimilar • Chronic Obstructive Pulmonary Disease

ABC-08: Phase Ib Trial of Acelarin in Combination With Cisplatin in Locally Advanced/ Metastatic Biliary Tract Cancers (clinicaltrials.gov) - P1; N=24; Not yet recruiting; Sponsor: Christie Hospital NHS Foundation Trust

New P1 trial • Biosimilar • Oncology

Reduction of gastrointestinal symptoms in Parkinson's disease after a switch from oral therapy to rotigotine transdermal patch: A non-interventional prospective multicenter trial. (PubMed) - "This study suggests that a switch from oral anti-PD medications to rotigotine transdermal patch may improve existing GI symptoms among patients with PD. Additional controlled studies are needed to confirm this finding."

Journal • Biosimilar • Oncology • Pain • Parkinson's Disease